 |
|
|
| |
Eltrombopag Therapy for HCV-Related Thrombocytopenia: Final Results of ENABLE 1, a Phase 3, Multicenter Study of Eltrombopag as an Adjunct for Antiviral Treatment of Hepatitis C Virus-Related Chronic Liver Disease Associated with Thrombocytopenia
|
| |
| |
Reported by Jules Levin
AASLD Nov 2011 SF
GSK's eltrombopag Platelet Booster Aids HCV Therapy
www.natap.org/2011/AASLD/AASLD_92.htm
Nov 14, 2011 - Overall, 66% of patients treated with eltrombopag plus peginterferon alpha 2a and ribavirin had an early virologic response compared with
|
| |
|
|
|
|
|
